Abstract
Introduction
Several recent studies have linked higher blood levels and/or dietary intakes of the longchain n-3 polyunsaturated fatty acids (PUFAs) with greater longevity. Plasma phospholipid n-3 PUFA levels were inversely associated with total mortality rates in the Cardiovascular Health Study, 1 and similar associations were seen for this endpoint with the red blood cell (RBC) content of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in the Heart and Soul Study. 2 This latter metric, called for simplicity the Omega-3 Index, has been proposed as a risk factor for death from cardiovascular disease (CVD). 3, 4 Consistent with these observations, there is an inverse relationship between the Omega-3 Index and the rate of telomere attrition, a marker of cellular aging. 5 Although early randomized controlled trials with n-3 PUFAs found reduced overall mortality, 6, 7 other more recent studies [8] [9] [10] [11] have not confirmed such a protective effect. Some of the potential reasons why recent studies may have yielded null results for intervention with n-3 PUFAs (background use of statins, 12 short follow-up periods, low n-3 PUFA doses, improvements in acute care, etc.) have been reviewed. 13, 14 In the present investigation, we examined the relations between RBC n-3 PUFA levels in participants in the Framingham Heart Study's (FHS's) Offspring cohort and total mortality as the primary endpoint, with secondary endpoints of death from CVD and other causes, and of incident coronary heart disease (CHD), CVD, and ischemic stroke.
Methods
The FHS is a longitudinal community-based cohort study that was initiated in 1948. Adult children of the original cohort were recruited in 1971 into the Framingham Offspring Cohort. The selection criteria for this cohort (and for the more racially diverse Framingham Omni Cohort) have previously been described. 15, 16 We evaluated Framingham Offspring/ shown in Table S7 . The hazard ratio for total CVD was significantly reduced in quintile 5 vs 1, but for total CHD or total stroke, no individual quintile differed significantly from the reference. Similar findings were observed in the full cohort (n = 2899) for total CHD and total stroke, but the relationship with total CVD was no longer statistically significant (Table  S8) . Using the modified Omega-3 Index (with DPA) did not change the pattern of results (Table S3) , and when Omega-3 risk categories were tested, the general pattern of relationships remained the same, but they were mostly nonsignificant (Table S4) . Finally, neither including n-6 PUFAs as covariates nor replacing the Omega-3 Index with the n-6:n-3 ratio altered the original results (Table S5) .
Individual RBC n-3 PUFAs and outcomes
The adjusted risk for experiencing the endpoints of interest by each of the four n-3 PUFAs separately is shown in Table 3 (unadjusted hazard ratios in Table S9 ). The plant-derived n-3 PUFA, ALA, was not significantly associated with reduced risk for any of the outcomes tested (Table 3 ). In general, as the levels of the EPA and (especially) DHA increased, risk for disease outcomes and total (and other) mortality decreased ( Table 3 ). The only outcome that DPA was (marginally, P = .059) associated with was death from other causes (Table 3) .
Omega-3 Index vs total cholesterol
In the head-to-head comparison of the Omega-3 Index and total cholesterol for total and CVD mortality and for the 3 CVD outcomes, the former metric was significantly associated with risk for 4 of the 5 outcomes, whereas the total cholesterol level, in the same models, was not associated with risk for any of these outcomes (Table 4) .
Discussion
In this study of participants in the Framingham Offspring study, the baseline Omega-3 Index at about 66 years of age was inversely associated with total mortality over the next 7 yearswith values of the Omega-3 Index significantly lower in those who died during follow-up than those who did not. The same was generally true for the 2 components of the Index, EPA and DHA, but not for RBC DPA n-3 or ALA. Findings for the Omega-3 Index persisted in a model adjusted for 18 other relevant variables including plasma lipids and C-reactive protein.
We recently reported similar findings to these in the Women's Health Initiative Memory Study where there was a significant inverse trend across quartiles of the Omega-3 Index for total mortality, with the highest quartile being at 22% lower risk for death compared with the lowest. 20 That study followed a nationwide sample of 6500, approximately 70-year-old women for 15 years. Kleber et al. also found a 9% decrease in risk for all-cause mortality per 1 SD increase in the Omega-3 Index after 10 years of follow-up in 3259 German CHD patients. 21 In the present study, we followed up 2500 men and women for half as long and found an interquintile risk reduction of 34%. We also found reduced risk for total CVD events, CHD events, and stroke. The approximately 50% lower risk for CVD mortality was, however, not statistically significant, most likely due to having only 58 events in the analysis (see below). Nevertheless, these findings are generally consistent with those of several metaanalyses that all linked higher n-3 PUFA biomarker levels with reduced risk for "coronary events" 22 or fatal CHD. 19, 23 This study was somewhat unique, however, in exploring relations between RBC n-3 PUFA levels instead of whole plasma or plasma phospholipid n-3 PUFAs. But since these markers of n-3 PUFA status are strongly intercorrelated, 24 this coherence is expected.
The causes of death most strongly associated with the Omega-3 Index were non-CVD and non-cancer, ie, "other" causes. By design, the FHS focused primarily on CVD outcomes, so details of the other causes of death are unavailable. An 11% reduction (per 1 SD increase in the Omega-3 Index) in risk for death from other causes was also seen in the women's study mentioned previously. 20 It is unclear what mechanism might explain this observation; but since n-3 PUFAs are known to have a wide variety of effects on cell membrane biology, 25, 26 a systemic impact of higher levels of these FAs on overall cellular health is possible. As noted earlier, several recent randomized trials of fish oil with total mortality as an endpoint have been null, but they typically showed trends toward a benefit. 27, 28 More consistent with our observations was a 2017 meta-analysis, 29 which found a significant 19% reduction in risk for coronary death associated with fish oil treatment. Two nonrandomized retrospective studies using governmental databases to track patient outcomes (one from England 30 and another from Italy 31 ) reported lower risk for all-cause mortality in those CHD patients who had been prescribed 1 g of fish oil at discharge. Finally, higher plasma long-chain n-3 FA levels were strongly associated with reduced risk for total mortality and CHD outcomes in renal transplant patients in Norway. 32 A somewhat surprising observation in this study was the low rate of CVD in this population, with only 17% of deaths being attributable to CVD (as opposed to 42% from cancer). Part of this is clearly the exclusion from the analysis set of participants with CVD at baseline, but even including these individuals, the CVD death rate was only 22%. This relatively low CVD death rate should perhaps not be surprising given the reduction in heart disease mortality in the United States over the last several decades. For example, the agestandardized death rate from heart disease per 100,000 people dropped from 520 in 1969 to 167 in 2014, a 68% decline. 33 With regard to the individual RBC n-3 PUFAs studied here, in the multivariable-adjusted model, ALA was not significantly related to any measured outcome in the quintile analysis. The null mortality findings for ALA agree with some previous studies, 34, 35 but higher circulating ALA levels (primarily plasma and plasma phospholipids) have been favorably associated with CVD death, 23 and ALA intake was associated with reduced total mortality in a large randomized clinical trial (RCT) from Spain. 36 So, evidence for ALA remains mixed. Turning to DPA, in the final model, it was not related with any examined outcome (although trends were favorable). This contrasts with a previous meta-analysis in which this FA (again, more often measured in whole plasma or plasma phospholipids) was inversely associated with risk for CVD death. 23 In light of this and other prior reports (eg, in heart failure 37 ), the utility of RBC DPA as a risk marker remains unclear. Nevertheless, because of the growing evidence for a beneficial role of DPA, 38 it is reasonable to ask why this FA is not a component of the Omega-3 Index. Including it would be reasonable if adding it to EPA and DHA improved the utility of the metric in risk assessment. In the present study, we compared the original and the modified Omega-3 Index (Table S3 ) and found essentially the same associations with outcomes for both. This would be expected since the correlation between these 2 predictor variables is 0.98. Hence, our findings provide no compelling reason to alter the original definition/components of the Omega-3 Index.
We found that the risk of stroke was inversely associated with the Omega-3 Index, but not in a linear manner, ie, hazard ratios were reduced only in the upper 2 quintiles; however, the trend across quintiles was significant. Risk reduction was largely associated with DHA, where risk was 59% lower in the fifth (vs the first) quintile (P < .05). An association between serum long-chain n-3 PUFA levels and stroke risk has been reported previously in cross-sectional studies. 39, 40 The impact of marine n-3 PUFA levels on ischemic stroke may extend beyond the risk of incident event. Lower plasma proportions of EPA and DHA have been shown to be independently associated with increased ischemic stroke severity and, for DHA, poor functional outcomes at 90 days after stroke. 41 In addition, a higher ratio of EPA or DHA to arachidonic acid in serum was associated with lower likelihood of early neurologic deterioration after ischemic stroke. 42 A 2012 meta-analysis of 32 observational cohorts and 13 n-3 RCTs reported inverse associations with stroke and fish intake, but no significant relations with either circulating biomarkers or with supplementation, 43 although a 2017 study of plasma phospholipid omega-3 FA and incident stroke from 3 cohorts found inverse relations with DHA as we did here. 44 A randomized, open-label study in patients surviving myocardial infarction 45 showed a reduction in risk of nonfatal stroke with n-3 FA supplementation, and an open-label study in Japan demonstrated no effect on primary prevention of stroke but a 20% relative reduction in recurrent total stroke with EPA supplementation. 46 However, some studies have found no relations between n-3 PUFA levels and stroke, 47, 48 so the n-3 PUFA and stroke literature is mixed, and more studies are needed.
A variety of exploratory analyses were conducted here. Given the controversies regarding the CVD effects of the n-6 PUFAs and the frequent use of the n-6:n-3 ratio, in one analysis we controlled for RBC n-6 PUFA levels and in another we directly compared the ratio with the Omega-3 Index. In neither case did the n-6 PUFAs add or detract from the omega-3 effect. Hence, this study found no support for using a combined metric with n-6 and n-3 PUFAs. Finally, we compared associations with disease outcomes for the Omega-3 Index with that of total cholesterol, one of the most well-known CVD risk factors. This analysis was undertaken to give some perspective of the relative sensitivity of these 2 biomarkers. In head-to-head comparisons with the same multivariable models, a higher Omega-3 Index was significantly associated with reduced risk for 4 of the 5 outcomes studies, but cholesterol was unrelated to risk for any outcome. This may be because about 38% of participants were on a cholesterol-lowering medication, and so cholesterol levels at baseline were therapeutically reduced; because 399 subjects with a diagnosis of CVD at baseline were excluded; or because those who were particularly susceptible to cholesterol-induced CHD may have already died. There is indeed some controversy regarding the predictive power of serum cholesterol in older individuals. 49 Nevertheless, in the unique context of this study in which we controlled for 17 other variables, cholesterol levels were unassociated with these outcomes. Whatever the reasons, this observation supports the need for further research to more clearly define the relative roles of traditional and emerging biomarkers in risk stratification.
The originally proposed (in 2004) clinical cut-points for the Omega-3 Index were <4% (high risk) and >8% (low risk). 3 Although these have recently been confirmed in a meta-analysis including 10 cohorts and over 27,000 subjects, 19 it was of interest to explore their utility in the present study as well. We found a significant trend across risk categories for total mortality and significant reductions in risk for the intermediate group compared with the high group, but not for the >8% category. This may reflect a nonlinear relationship between the Omega-3 Index and risk as has been suggested by others, 25 or the fact that only 10% of the sample was in the >08% category. Nevertheless, the hazard ratio of 0.69 for any death in the >8% category is at least suggestive of lower risk.
As alluded to earlier, mechanisms that may explain the associations between higher RBC n-3 PUFA and improved longevity and reduced CVD risk are not clearly understood, but there are beneficial effects of these FAs on a variety of CV risk factors. These include reductions in serum triglyceride levels, 50 blood pressure, 51 platelet aggregation, 52 heart rate, 53 susceptibility to ventricular fibrillation (in some settings), 54 inflammatory markers, 55, 56 and plaque vulnerability 57, 58 along with improvements in endothelial function. 59 The observation that blood EPA + DHA levels are independently associated with slower rates of telomere shortening, 5 a purported marker of "cellular aging," is yet another favorable biomarker relationship, but it is not a molecular mechanism.
From an observational study, we cannot conclude that raising the Omega-3 Index will have heart benefits and/or prolong life. Nevertheless, it is instructive to consider how much more EPA + DHA an individual might need to consume to move the median Omega-3 Index in quintile 1 (3.7%) to that in quintile 5 (7.8%). Based on a recent dose-response study, 60 one can estimate that it would take about 1300 more mg of EPA + DHA per day to do this. This amount of EPA + DHA could be obtained from a single serving (100 g) of farmed salmon 61 daily. Alternatively, 4 standard fish oil pills per day would suffice. Several early omega-3 RCTs used 800-1000 mg/d and reported reduced total mortality, 6, 7, 62 whereas other more recent studies at the same dose have not. 9, 11, 63 Several possible reasons for this discrepancy have been proposed. 64, 65 
Strengths and limitations
The strengths of our investigation include the relatively large sample size from a wellcharacterized community, the unambiguous nature of the primary endpoint, and the use of an objective and standardized biomarker of PUFA exposure that has low biological variability. 66 Weaknesses include the assessment of PUFA exposure at only one point in time (which cannot capture changes in PUFA status that may have occurred during follow-up) and the largely Caucasian cohort (which precludes firm conclusions regarding other races). Also, the relatively low event rates, especially for CVD death, limited our ability to detect associations with this endpoint. Although clearly affected by omega-3 PUFA intake, other factors can influence the Omega-3 Index such as smoking and body weight, 67 both of which were controlled for here. What we did not (and could not) control for is heritability, which we showed previously to explain about 24% of the variability in this biomarker. 67 In the same vein, we did not include in our models the intake of key nutrients (kilocalories, saturated FAs, salt, fiber, etc.), which might contribute to the relationships reported here. However, by controlling for some of the physiological/metabolic consequences of consuming diets of poor quality (body weight, blood pressure, hyperlipidemia, and CRP levels), as well as for socioeconomic variables (which themselves track with poor diets), it is unlikely that including individual nutrients would have altered the outcome of the study. As always, the presence of residual or unmeasured confounding also precludes inferences about causality. For example, despite controlling for multiple lifestyle/health factors, higher omega-3 PUFA levels may simply be a marker for a healthier overall diet and behaviors, which themselves, independent of the omega-3 levels, may be cardioprotective.
In conclusion, we observed that higher RBC levels of n-3 PUFAs were associated with greater longevity and reduced risk for several CVD-related endpoints in this communitybased sample. These findings, in the context of the totality of available evidence on this topic, provide further support for a role for the use of the Omega-3 Index in risk stratification algorithms.
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APPENDIX Table S1
Distribution of outcomes (n = 2500) All significant hazard ratios/P-values are shown in bold italics.
Adjusted for all variables in Table 1 . .04 * CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval. * P < .05 † P < .01 Table S5 The Omega-3 Index vs the n-6:n-3 ratio and vs the Omega-3 Index adjusting for all n-6 fatty acids (n = 2500) .02 * CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval. * P < .05 † P < .01 ‡ P < .001.
All significant hazard ratios/P-values are shown in bold italics.
Adjusted for all variables in Table 1 except baseline CVD.
Table S7
Unadjusted risk of events by Omega-3 Index (n = 2500) CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval. * P < .05 Table S8 Risk CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval. * P < .05 Table S9 Unadjusted .03
.
13
93
.77
.25
.41
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval. All significant hazard ratios/P-values are shown in bold italics. * P < .05 † P < .01 ‡ P < .001. Relations between quintiles of the Omega-3 Index and hazard ratios (+95% confidence interval) for death from CVD (n = 58), cancer (n = 146), other causes (n = 128), and all causes (n = 350, including 18 of unknown causes). Data are from 2500 participants free of baseline CVD followed for a median of 7.3 years. Adjusted for all variables in Table 1 . Pvalues for trend are shown above the columns. CVD, cardiovascular disease; CHD, coronary heart disease.
Harris et al. .054
.06
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval. * P < .05 † P < .01.
All significant hazard ratios/P-values are shown in bold italics. § Adjusted for all variables in Table 1 CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval. * P < .05 † P < .01
All significant hazard ratios/P-values are shown in bold italics. § Hazard ratios presented here were adjusted for all variables in Table 1 with the addition of grouped total cholesterol (and removing total cholesterol to high-density lipoprotein cholesterol ratio) and the grouped Omega-3 Index.
ǁ Linear trend test models were fit for both the Omega-3 Index and TC simultaneously, after adjusting for variables as described in footnote " § ".
